{
    "name": "monomethyl fumarate",
    "comment": "Rx",
    "other_names": [
        "Bafiertam"
    ],
    "classes": [
        "Multiple Sclerosis Treatments",
        "Immunomodulators"
    ],
    "source": "https://reference.medscape.com/drug/bafiertam-monomethyl-fumarate-4000037",
    "pregnancy": {
        "common": [
            "No adequate data available on the use of MMF or its prodrug in pregnant females"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animals, adverse effects on offspring survival, growth, sexual maturation, and neurobehavioral function were observed when DMF was administered during pregnancy and lactation at clinically relevant doses"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data available on presence of DMF or MMF in human milk",
            "Effects on breastfed infants and on milk production are unknown",
            "Consider the motherâ€™s clinical need and any potential adverse effects on the breastfed infants from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to MMF, DMF, diroximel fumarate, or to any of its excipients",
                "Taking DMF or diroximel fumarate"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Clinically significant cases of liver injury reported; onset ranges from a few days to several months after initiating; discontinue if clinically significant drug-induced liver injury is suspected",
                "May cause flushing (eg, warmth, redness, itching, and/or burning sensation)"
            ],
            "specific": [
                {
                    "type": "Anaphylaxis and angioedema",
                    "description": [
                        "Anaphylaxis and angioedema after initial dose or at any time during treatment may occur",
                        "Signs and symptoms have included difficulty breathing, urticaria, and swelling of the throat and tongue"
                    ]
                },
                {
                    "type": "Progressive multifocal leukoencephalopathy",
                    "description": [
                        "Progressive multifocal leukoencephalopathy (PML) has occurred with DMF",
                        "Withhold dose at first sign or symptom suggestive of PML and perform diagnostic evaluation",
                        "Typical symptoms (eg, progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, changes in thinking, memory changes, orientation leading to confusion, personality changes) may progress over days to weeks",
                        "Monitor with MRI for signs consistent with PML and investigate any suspicious findings to allow for an early diagnosis of PML, if present"
                    ]
                },
                {
                    "type": "Herpes zoster and other serious opportunistic infections",
                    "description": [
                        "Serious cases of herpes zoster reported; these events may occur at any time during treatment",
                        "Monitor for signs and symptoms of herpes zoster",
                        "If herpes zoster occurs, administer appropriate treatment",
                        "Other serious opportunistic infections reported, including serious viral (herpes simplex virus, West Nile virus, cytomegalovirus), fungal (Candida and Aspergillus), and bacterial (Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis) infections",
                        "Consider withholding treatment in patients with herpes zoster or other serious infections until the infection has resolved"
                    ]
                },
                {
                    "type": "Lymphopenia",
                    "description": [
                        "May decrease lymphocyte counts",
                        "Consider interrupting dose in patients with lymphocyte counts <0.5 x 10",
                        "9",
                        "/L persisting for >6 months",
                        "Continue to monitor CBC count until their recovery if therapy is discontinued or interrupted because of lymphopenia",
                        "Consider withholding treatment from patients with serious infections until resolution",
                        "Decide whether or not to restart treatment based on clinical circumstances"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "DMF or diroximel fumarate",
                        "Both DMF and diroximel fumarate are metabolized to MMF",
                        "Therefore, coadministration of MMF with DMF or diroximel fumarate is contraindicated ",
                        "MMF may initiate the day following discontinuation of either of these drugs"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "monomethyl fumarate, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "monomethyl fumarate, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "monomethyl fumarate, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "monomethyl fumarate, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "monomethyl fumarate, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "monomethyl fumarate, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "monomethyl fumarate and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod, monomethyl fumarate.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration with immunosuppressive therapies may increase the risk of additive immune effects during therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs in order to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and monomethyl fumarate both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Data obtained from clinical trials of prodrug dimethyl fumarate",
            "percent": "40"
        },
        {
            "name": "DMF",
            "percent": "18"
        },
        {
            "name": "which is metabolized to MMF",
            "percent": "14"
        },
        {
            "name": "Flushing",
            "percent": "12"
        },
        {
            "name": "Abdominal pain",
            "percent": "9"
        },
        {
            "name": "Diarrhea",
            "percent": "8"
        },
        {
            "name": "Nausea",
            "percent": "8"
        },
        {
            "name": "Vomiting",
            "percent": "6"
        },
        {
            "name": "Pruritus",
            "percent": "5"
        },
        {
            "name": "Rash",
            "percent": "5"
        },
        {
            "name": "Albumin urine present",
            "percent": "4"
        },
        {
            "name": "Erythema",
            "percent": "2"
        },
        {
            "name": "Dyspepsia",
            "percent": "2"
        },
        {
            "name": "AST increased",
            "percent": "3"
        },
        {
            "name": "Lymphopenia",
            "percent": "2"
        },
        {
            "name": "A transient increase in mean eosinophil counts during first",
            "percent": null
        },
        {
            "name": "months of treatment",
            "percent": null
        },
        {
            "name": "Liver function abnormalities",
            "percent": null
        },
        {
            "name": "AST",
            "percent": null
        },
        {
            "name": "ALT",
            "percent": null
        },
        {
            "name": "x ULN with concomitant elevations in total bilirubin",
            "percent": null
        },
        {
            "name": "x ULN",
            "percent": null
        },
        {
            "name": "Infections",
            "percent": null
        },
        {
            "name": "Herpes zoster infection",
            "percent": null
        },
        {
            "name": "other serious opportunistic infections",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Acute pancreatitis",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Rhinorrhea",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        }
    ]
}